ADVENTRX Pharmaceuticals to Be Listed on AMEX

ADVENTRX Pharmaceuticals to Be Listed on AMEX 


SAN DIEGO, April 27  /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc.
(ADVENTRX or "Company")  (BULLETIN BOARD: AVRX)  announced today that it has
received approval from the American Stock Exchange (the "Exchange") to list its
share of common stock in the Exchange under trading symbol "ANX."

This approval is contingent upon ADVENTRX being in full compliance with all
applicable listing standards on the date it begins trading on the Exchange. 
The Company expects to begin trading on the Exchange on April 29, 2004.

"Listing on the Exchange is an important milestone and an initial step to gain
greater visibility and recognition for the Company from the investment
community," said Nicholas Jon Virca, ADVENTRX President and CEO. "We anticipate
this to be one in a series of truly positive steps for the organization and our
shareholders."

ADVENTRX will be represented by the specialist firm of Cohen Specialists LLC on
the Exchange trading floor.

About ADVENTRX

ADVENTRX Pharmaceuticals Inc. is a biopharmaceutical research and development
company whose business strategy is to commercialize leading edge medical
research through licensing agreements with prominent universities and research
institutions. The Company focuses on cancer and antiviral research to launch
products that either extend the usefulness of current therapies or replace
marginal therapies with new approaches to treatment.

This press release contains forward-looking statements within the meaning of
the "safe harbor" provisions of the Private Securities Litigation Reform Act of
1995. Such statements are made based on management's current expectations and
beliefs. Actual results may vary from those currently anticipated based upon a
number of factors, including uncertainties inherent in the drug development
process, the timing and success of clinical trials, the validity of research
results, and the receipt of necessary approvals from the United States Food and
Drug Administration. The Company undertakes no obligation to release publicly
any revisions, which may be made to reflect events or circumstances after the
date hereof.

   Contact:
   The Ruth Group
   Investors:  Stephanie Carrington
   646-536-7017
   Media:  Cynthia Isaac, Ph.D.
   646-536-7028


DATASOURCE: ADVENTRX Pharmaceuticals, Inc.



CONTACT:  Investors - Stephanie Carrington, [phone], or Media -

Cynthia Isaac, Ph.D., [phone], both of The Ruth Group, for ADVENTRX

Pharmaceuticals, Inc.

Copyright